ACI's 6th Annual Summit on Biosimilars
The Definitive Forum on the Legal, Regulatory, Patent, and Commercial Realities of Follow-On Biologics
For the past six years, since the passage of the historic Biologics Price Competition & Innovation Act (BPCIA) which first set the stage for biosimilars in 2010, the key figures shaping the evolving US biosimilars landscape have convened at ACI's annual conference to formulate solutions to the challenges facing the industry. Now that the FDA has given its stamp of approval to at least one biosimilar and litigation is already winding its way through the Courts, arm yourself with an immediate action plan to prepare for the hard-fought battle to protect or increase market share which is sure to come.
Paul Hastings partners Gerald Flattmann and Melanie Rupert are featured panelists for this program.
For additional information and to register, visit